Chiron Biotech
Develops a fast multimaterial inkjet bioprinting platform for biomedical research and production, enabling creation of complex biomimetic tissues with high speed and resolution.
- CEO / Founder
- Matteo Baldassari
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $58.3K
- Latest Round
- Grant
- Key Investors
- Eurostars
Technology & Products
Key Products
Armadillo Bio (multimaterial inkjet platform); Chameleon desktop bioprinter
Technological Advantage
Proprietary inkjet bioprinting technology allows multimaterial deposition of biomaterials and living cells, protected by patents (specific numbers not found), enabling high-throughput biofabrication for research and industrial applications.
Differentiation
Value Proposition
Reduces tissue engineering time by enabling rapid prototyping of biomimetic tissues for drug discovery and personalized medicine, with customizable hardware and software for tailored applications.
How They Differentiate
Offers a customizable multimaterial inkjet platform with higher speed and resolution compared to competitors like CELLINK's extrusion-based systems, focusing on bio-inkjet for precise tissue micro-environments.
Market & Competition
Target Customers
Biomedical researchers, pharmaceutical companies, regenerative medicine labs
Industry Verticals
Biomedical; Pharmaceutical; Regenerative Medicine
Competitors
Aspect Biosystems; Cyfuse; CELLINK
Growth & Milestones
Growth Metrics
First ArmadilloBio multimaterial inkjet platform delivered to TU Eindhoven; partnership with medac for animal-free drug testing; collaboration with IPC, University Medical Center of Utrecht, and Trinity College Dublin.
Major Milestones
First ArmadilloBio platform delivered to TU Eindhoven; Partnership with medac for animal-free drug testing
Notable Customers
TU Eindhoven